Featured News

On behalf of the entire celiac disease patient community, thank you for your participation in the Celiac Disease Foundation’s 2023 Gift of Hope campaign! Our annual year-end initiative to raise awareness and funds for celiac disease research was extraordinary – all thanks to YOU.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

Researchers found that roughly one-third of celiac patients reported using probiotics for perceived health benefits, despite the lack of evidence that probiotics are an effective treatment for celiac disease symptoms.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.

Researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation presented a study which concluded that despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives.

A study led by Columbia University and Celiac Disease Foundation researchers examined probiotic use among celiac disease patients and was an Outstanding Poster Presenter recipient at the 2020 ACG Annual Scientific Meeting.

Thanks to your generous support, we are deploying iCureCeliac and iQualifyCeliac, as well as other assets unique to the Foundation, to further celiac disease drug development.

We put together a list of some of the most common perceived barriers to participating in clinical trials, and how to overcome them.

CEO Marilyn G. Geller speaks at the 18th International Celiac Disease Symposium (ICDS).